NCT04608409View on ClinicalTrials.gov

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

Lapatinib and Paclitaxel

Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.

Trial Locations (1)

40536

Markey Cancer Center, Lexington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Frederick R. Ueland, M.D.

OTHER

NCT04608409 - Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | Biotech Hunter | Biotech Hunter